Clinical Trial Update: An Open-Label Phase 2 Study of Ofatumumab (Arzerra) in Combination With Oral GSK2110183 in the Treatment of Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL) [Phase 2]

View source ↗

Summary

An open-label Phase 2 study evaluating the combination of Ofatumumab (Arzerra) with GSK2110183 in relapsed/refractory chronic lymphocytic leukemia has completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• GSK2110183
• Ofatumumab (ofatumumab)

Snippet

Sponsor: University Health Network, Toronto | Conditions: Chronic Lymphocytic Leukemia (CLL) | Phase 2 | Status: COMPLETED | Results posted: 2019-09-24